邬素芳教授承担和发起多项临床研究，牵头开展了“靶向LSD1协同PD-L1拮抗剂治疗宫颈癌”等临床转化研究。作为课题骨干参与国家重大研发计划，致力于构建适合国人的宫颈癌筛查方案及子宫内膜癌保留生育功能的多学科诊疗体系。同时，长期致力于妇科肿瘤的基础与转化研究，尤其在宫颈癌的发病机制与精准治疗领域取得了系统性和创新性的成果，不仅深化了对宫颈癌发病分子网络的理解，更将LSD1确立为极具潜力的治疗靶点。目前主持国家自然基金4项、省市级课题8项，教学课题5项，国家发明专利2项，以第一/通讯作者在Signal Transduction and Targeted Therapy、Journal of Hematology & Oncology等国际顶级期刊发表SCI论文50余篇，累计影响因子超过350分。研究成果被广泛引用，推动了对宫颈癌肿瘤微环境、代谢重编程及免疫调控的认识。
Professor Wu Sufang has led and initiated multiple clinical research projects, spearheading translational clinical studies such as "Targeting LSD1 in Combination with PD-L1 Inhibitors for Cervical Cancer Treatment." As a key investigator in national major R&D programs, she is committed to developing cervical cancer screening strategies tailored for the Chinese population and establishing a multidisciplinary diagnosis and treatment system for fertility preservation in endometrial cancer patients.
She has also long been dedicated to basic and translational research in gynecological tumors, achieving systematic and innovative results, particularly in the pathogenesis of cervical cancer and precision therapy. Her work has not only deepened the understanding of the molecular network underlying cervical cancer development but also identified LSD1 as a highly promising therapeutic target.
To date, she has secured 4 National Natural Science Foundation projects, 8 provincial/ministerial-level grants, 5 teaching research projects, and holds 2 national invention patents. As the first or corresponding author, she has published over 50 SCI papers in top-tier international journals such as Signal Transduction and Targeted Therapy and Journal of Hematology & Oncology, with a cumulative impact factor exceeded 350. Her research findings have been widely cited and have significantly advanced the understanding of the tumor microenvironment, metabolic reprogramming, and immune regulation in cervical cancer.
【部分代表性论著（近5年内）】
Du H, Xu T, Yu S, Wu S, Zhang J. Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct Target Ther. 2025 Aug 4;10(1):245. PMID: 40754534; PMCID.
Li S, Li X, Yang YB, Wu SF. YAP/TAZ-TEAD activity promotes the malignant transformation of cervical intraepithelial neoplasia through enhancing the characteristics and Warburg effect of cancer stem cells. Apoptosis. 2024 Aug;29(7-8):1198-1210. PMID: 38553612.
Yang Y, Wang M, Sang WL, Zhang YY, Liu W, Wu SF. Student-Driven Course-Based Undergraduate Research Experience (CUREs) Projects in Identifying Vaginal Microorganism Species Communities to Promote Scientific Literacy Skills. Front Public Health. 2022 Apr 28;10:870301. PMID: 35570970.
Yang R, Yu S, Xu T, Zhang J, Wu S. Emerging role of RNA sensors in tumor microenvironment and immunotherapy. J Hematol Oncol. 2022 Apr 12;15(1):43. PMID: 35413927.
Yu S, Yang R, Xu T, Li X, Wu S, Zhang J. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer. Gynecol Oncol. 2022 Nov;167(2):342-353. PMID: 36114029.
Yu S, Li X, Ma M, Yang R, Zhang J, Wu S. The Immunological Contribution of a Novel Metabolism-Related Signature to the Prognosis and Anti-Tumor Immunity in Cervical Cancer. Cancers (Basel). 2022 May 13;14(10):2399. PMID: 35626004.
Xu T, Yu S, Zhang J, Wu S. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers. J Hematol Oncol. 2021 Oct 30;14(1):181. PMID: 34717710.
Xu S, Wang X, Yang Y, Li Y, Wu S. LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer. Cell Death Dis. 2021 Mar 17;12(4):282. PMID: 33731702.
Yu S, Li X, Zhang J, Wu S. Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer. Front Immunol. 2021 Sep 3;12:709493. PMID: 34539641.
【项目负责人承担科研课题（部分）】
1.国家自然基金面上项目, 82472281，LSD1调控HPV E7-HELQ介导微同源末端连接促进宫颈上皮细胞HPV整合的机制研究， 2025.01.01-2028.12.31
2.国家自然基金面上项目, 82272334，外泌体LSD1调控巨噬细胞铁死亡介导HPV促进宫颈病变细胞免疫逃逸的机制研究， 2023.01.01-2026.12.31
3.国家自然基金面上项目, 81971340， HPV E7-LSD1-CD47介导病毒免疫逃逸进而驱动宫颈病变的机制研究. 2020.01.01-2023.12.31
4.国家自然基金青年项目. 81201541. HPV E7基因抑制LSD1促进宫颈癌细胞EMT的分子机制
